Regeneron Antibody Drug Temporarily Protects Against Covid-19, Preliminary Data Show

Source: WSJ

The drug cocktail reduced infections in a continuing late-stage study, the company reported

Regeneron Pharmaceuticals Inc. said its antibody drug reduced coronavirus infections by half in people at high risk, a preliminary sign the therapy could be given to temporarily prevent Covid-19.

None of the patients receiving the drug developed symptoms from the virus, Regeneron said Tuesday, providing an interim analysis of a continuing study.

Given the drug’s performance, Regeneron said it would discuss the possibility of authorizing the drug as a temporary vaccine with U.S. regulators. Complete trial data from the study is expected early in the second quarter, the company said.

Regeneron’s data indicate that antibody-based drugs could help provide temporary protection against Covid-19 as the U.S. and other countries grapple with limited supplies of vaccines. The drugs are thought to provide protection for at least one month.

Eli Lilly & Co. said last week that its antibody drug also prevented many infections in a study of nursing-home patients.

Read further

Categories: Health

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.